Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 9/20 | 0.43 |
| ▸ | PARP2 | Q9UGN5 | 8/20 | 0.43 |
| ▸ | PARP6 | Q2NL67 | 7/20 | 0.43 |
| ▸ | PARP3 | Q9Y6F1 | 7/20 | 0.43 |
| ▸ | TNKS | O95271 | 5/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.38 |
| ▸ | TUBB | P07437 | 1/20 | 0.38 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.38 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.38 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.38 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.38 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.38 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.38 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.38 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12311747 | 0.87 | PARP1 (0.44) | PARP1PARP2PARP6PARP3TNKS | |
| SCHEMBL13010238 | 0.85 | GAA (0.40) | PARP1PARP2PARP6PARP3TNKS | |
| SCHEMBL10107817 | 0.80 | HRH4 (0.41) | PARP1PARP2PARP6PARP3TNKS | |
| SCHEMBL10108063 | 0.79 | HRH4 (0.41) | PARP1PARP2PARP6PARP3TNKS | |
| SCHEMBL20017621 | 0.78 | TUBB4A (0.42) | PARP1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL10107921 | 0.78 | CHRM2 (0.41) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL12311749 | 0.78 | KDM4E (0.47) | PARP1PARP2PARP6PARP3TNKS | |
| SCHEMBL12336932 | 0.76 | CYP19A1 (0.52) | PARP1PARP2PARP6PARP3TNKS | |
| SCHEMBL10108225 | 0.74 | OPRL1 (0.48) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL10102431 | 0.72 | NPC1 (0.61) | PARP1PARP2PARP6PARP3TNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687277-B1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-04 | — | — | EP | disclosed |
| US-9115084-B2 | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2015-08-25 | — | — | US | disclosed |
| US-9115084-B2 | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2015-08-25 | — | — | US | disclosed |
| US-20130237528-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-09-12 | — | — | US | disclosed |
| US-20130237528-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-09-12 | — | — | US | disclosed |
| US-8450486-B2 | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-05-28 | — | — | US | disclosed |
| US-20120046274-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | MABIRE DOMINIQUE JEAN-PIERRE (FR) | 2012-02-23 | — | — | US | disclosed |
| US-20120046274-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | MABIRE DOMINIQUE JEAN-PIERRE (FR) | 2012-02-23 | — | — | US | disclosed |
| US-8071612-B2 | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2011-12-06 | — | — | US | disclosed |
| US-8071612-B2 | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2011-12-06 | — | — | US | disclosed |
| US-20110124673-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | MABIRE DOMINIQUE JEAN-PIERRE | 2011-05-26 | — | — | US | disclosed |
| US-20110124673-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | MABIRE DOMINIQUE JEAN-PIERRE | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124673-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | PARP1, PARP2, PARP6 | PARP1 1/4885PARP2 2/4885PARP6 3/4885 |
| US-20130237528-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | PARP1, PARP2, PARP6 | PARP1 1/4885PARP2 2/4885PARP6 3/4885 |
| US-20120046274-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | PARP1, PARP2, PARP6 | PARP1 1/4885PARP2 2/4885PARP6 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.